These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 17199134

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.
    Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A, Arai Y, Usami M, Naito S, Kanetake H, Ohashi Y.
    Jpn J Clin Oncol; 2004 Jan; 34(1):20-8. PubMed ID: 15020659
    [Abstract] [Full Text] [Related]

  • 3. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H.
    BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [Abstract] [Full Text] [Related]

  • 4. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 5. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [Abstract] [Full Text] [Related]

  • 6. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group.
    BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
    [Abstract] [Full Text] [Related]

  • 7. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [Abstract] [Full Text] [Related]

  • 8. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Sayyid RK, Evans A, Hersey K, Maloni R, Hurtado-Coll A, Kulkarni G, Finelli A, Zlotta AR, Hamilton R, Gleave M, Fleshner NE.
    Clin Cancer Res; 2017 Apr 15; 23(8):1974-1980. PubMed ID: 27756786
    [Abstract] [Full Text] [Related]

  • 9. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P.
    BJU Int; 2012 Dec 15; 110(11):1721-8. PubMed ID: 22500884
    [Abstract] [Full Text] [Related]

  • 10. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
    Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Urology; 1995 May 15; 45(5):745-52. PubMed ID: 7538237
    [Abstract] [Full Text] [Related]

  • 11. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R, Pahalajani G, Agarwal A, Zippe C.
    Asian J Androl; 2007 Mar 15; 9(2):253-8. PubMed ID: 17334592
    [Abstract] [Full Text] [Related]

  • 12. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y, Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer.
    Cancer; 2009 Aug 01; 115(15):3437-45. PubMed ID: 19536889
    [Abstract] [Full Text] [Related]

  • 13. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
    Maekawa S, Maegawa M, Ushida H, Inoue K, Kaneko Y, Ohmori K, Nishimura K.
    Hinyokika Kiyo; 2001 Aug 01; 47(8):553-5. PubMed ID: 11579594
    [Abstract] [Full Text] [Related]

  • 14. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ.
    Urology; 1997 Sep 01; 50(3):330-6. PubMed ID: 9301693
    [Abstract] [Full Text] [Related]

  • 15. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
    Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M.
    J Urol; 2005 Aug 01; 174(2):547-52; discussion 552. PubMed ID: 16006889
    [Abstract] [Full Text] [Related]

  • 16. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P, Roder MA.
    Expert Rev Anticancer Ther; 2008 Mar 01; 8(3):361-9. PubMed ID: 18366284
    [Abstract] [Full Text] [Related]

  • 17. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group.
    BJU Int; 2006 Feb 01; 97(2):247-54. PubMed ID: 16430622
    [Abstract] [Full Text] [Related]

  • 18. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep 01; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 19. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I.
    J Urol; 2000 Nov 01; 164(5):1579-82. PubMed ID: 11025708
    [Abstract] [Full Text] [Related]

  • 20. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T.
    BJU Int; 2006 Sep 01; 98(3):563-72. PubMed ID: 16771791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.